论文部分内容阅读
目的:观察非霍奇金淋巴瘤采用美罗华联合“环磷酰胺+吡柔比星+长春新碱+泼尼松”(CHOP)方案治疗的临床效果。方法:随机选取2010年1月-2012年1月期间治疗的66例非霍奇金淋巴瘤患者,分为A、B两组。A组患者行CHOP方案治疗,B组患者行美罗华联合CHOP方案治疗,比较两组患者临床治疗效果。结果:A组患者治疗总有效率为54.5%,B组患者治疗总有效率为90.9%。B组患者治疗有效率更高,差异具有统计学意义(P<0.05)。B组患者不良反应发生率、2年生存率优于A组,差异具有统计学意义(P<0.05)。结论:美罗华联合CHOP方案治疗非霍奇金淋巴瘤效果显著。
Objective: To observe the clinical effect of rituximab combined with cyclophosphamide, pirarubicin + vincristine + prednisone (CHOP) regimen in non-Hodgkin’s lymphoma. Methods: Sixty-six non-Hodgkin’s lymphoma patients were randomly selected from January 2010 to January 2012, and divided into A and B groups. Patients in group A were treated with CHOP regimen. Patients in group B were treated with rituximab combined with CHOP regimen, and the clinical effects were compared between the two groups. Results: The total effective rate of treatment in group A was 54.5%, and the total effective rate in group B was 90.9%. Patients in group B were more effective in treatment, the difference was statistically significant (P <0.05). The incidence of adverse reactions and the 2-year survival rate in group B were better than those in group A, with significant difference (P <0.05). Conclusion: The combination of rituximab and CHOP regimen is effective in treating non-Hodgkin’s lymphoma.